A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development

  1. Christie Ciarlo
  2. Charles K Kaufman
  3. Beste Kinikoglu
  4. Jonathan Michael
  5. Song Yang
  6. Christopher D′Amato
  7. Sasja Blokzijl-Franke
  8. Jeroen den Hertog
  9. Thorsten M Schlaeger
  10. Yi Zhou
  11. Eric Liao
  12. Leonard I Zon  Is a corresponding author
  1. Boston Children's Hospital, United States
  2. Washington University School of Medicine, United States
  3. Harvard Medical School, United States
  4. Koninklijke Nederlandse Akademie van Wetenschappen (KNAW), University Medical Center Utrecht, Netherlands

Abstract

The neural crest is a dynamic progenitor cell population that arises at the border of neural and non-neural ectoderm. The inductive roles of FGF, Wnt, and BMP at the neural plate border are well established, but the signals required for subsequent neural crest development remain poorly characterized. Here, we conducted a screen in primary zebrafish embryo cultures for chemicals that disrupt neural crest development, as read out by crestin:EGFP expression. We found that the natural product caffeic acid phenethyl ester (CAPE) disrupts neural crest gene expression, migration, and melanocytic differentiation by reducing Sox10 activity. CAPE inhibits FGF-stimulated PI3K/Akt signaling, and neural crest defects in CAPE-treated embryos are suppressed by constitutively active Akt1. Inhibition of Akt activity by constitutively active PTEN similarly decreases crestin expression and Sox10 activity. Our study has identified Akt as a novel intracellular pathway required for neural crest differentiation.

Data availability

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Christie Ciarlo

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Cambridge, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2876-2432
  2. Charles K Kaufman

    Department of Medicine, Washington University School of Medicine, St. Louis, United States
    Competing interests
    No competing interests declared.
  3. Beste Kinikoglu

    Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  4. Jonathan Michael

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  5. Song Yang

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  6. Christopher D′Amato

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  7. Sasja Blokzijl-Franke

    Hubrecht Institute, Koninklijke Nederlandse Akademie van Wetenschappen (KNAW), University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    No competing interests declared.
  8. Jeroen den Hertog

    Hubrecht Institute, Koninklijke Nederlandse Akademie van Wetenschappen (KNAW), University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    No competing interests declared.
  9. Thorsten M Schlaeger

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  10. Yi Zhou

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  11. Eric Liao

    Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  12. Leonard I Zon

    Stem Cell Program and Hematology/Oncology, Boston Children's Hospital, Boston, United States
    For correspondence
    zon@enders.tch.harvard.edu
    Competing interests
    Leonard I Zon, L.I.Z. is a founder and stock holder of Fate Therapeutics, Marauder Therapeutics, and Scholar Rock..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0860-926X

Funding

National Institutes of Health (F31CA180313)

  • Christie Ciarlo

Melanoma Research Alliance

  • Leonard I Zon

Lawrence Ellison Foundation

  • Leonard I Zon

Howard Hughes Medical Institute

  • Leonard I Zon

National Institutes of Health (R01CA103846)

  • Leonard I Zon

National Institutes of Health (RO3DE024490)

  • Eric Liao

National Institutes of Health (K08AR061071)

  • Charles K Kaufman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Zebrafish were maintained under standard protocols approved by the Boston Children's Hospital (BCH) Institutional Animal Care and Use Committee (IACUC) (protocol # 14-10-2789R).

Copyright

© 2017, Ciarlo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,291
    views
  • 573
    downloads
  • 28
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Christie Ciarlo
  2. Charles K Kaufman
  3. Beste Kinikoglu
  4. Jonathan Michael
  5. Song Yang
  6. Christopher D′Amato
  7. Sasja Blokzijl-Franke
  8. Jeroen den Hertog
  9. Thorsten M Schlaeger
  10. Yi Zhou
  11. Eric Liao
  12. Leonard I Zon
(2017)
A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development
eLife 6:e29145.
https://doi.org/10.7554/eLife.29145

Share this article

https://doi.org/10.7554/eLife.29145

Further reading

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Ruben Sebastian-Perez, Shoma Nakagawa ... Maria Pia Cosma
    Research Article

    Chromocenters are established after the 2-cell (2C) stage during mouse embryonic development, but the factors that mediate chromocenter formation remain largely unknown. To identify regulators of 2C heterochromatin establishment in mice, we generated an inducible system to convert embryonic stem cells (ESCs) to 2C-like cells. This conversion is marked by a global reorganization and dispersion of H3K9me3-heterochromatin foci, which are then reversibly formed upon re-entry into pluripotency. By profiling the chromatin-bound proteome (chromatome) through genome capture of ESCs transitioning to 2C-like cells, we uncover chromatin regulators involved in de novo heterochromatin formation. We identified TOPBP1 and investigated its binding partner SMARCAD1. SMARCAD1 and TOPBP1 associate with H3K9me3-heterochromatin in ESCs. Interestingly, the nuclear localization of SMARCAD1 is lost in 2C-like cells. SMARCAD1 or TOPBP1 depletion in mouse embryos leads to developmental arrest, reduction of H3K9me3, and remodeling of heterochromatin foci. Collectively, our findings contribute to comprehending the maintenance of chromocenters during early development.

    1. Developmental Biology
    Yunfei Mu, Shijia Hu ... Hongjun Shi
    Research Article

    Notch signaling has been identified as a key regulatory pathway in patterning the endocardium through activation of endothelial-to-mesenchymal transition (EMT) in the atrioventricular canal (AVC) and proximal outflow tract (OFT) region. However, the precise mechanism underlying Notch activation remains elusive. By transiently blocking the heartbeat of E9.5 mouse embryos, we found that Notch activation in the arterial endothelium was dependent on its ligand Dll4, whereas the reduced expression of Dll4 in the endocardium led to a ligand-depleted field, enabling Notch to be specifically activated in AVC and OFT by regional increased shear stress. The strong shear stress altered the membrane lipid microdomain structure of endocardial cells, which activated mTORC2 and PKC and promoted Notch1 cleavage even in the absence of strong ligand stimulation. These findings highlight the role of mechanical forces as a primary cue for endocardial patterning and provide insights into the mechanisms underlying congenital heart diseases of endocardial origin.